Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;9(1):35-45.
doi: 10.21037/jgo.2017.10.13.

Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study

Brice Jabo  1 , Matthew J Selleck  2 , John W Morgan  3 , Sharon S Lum  2 , Khaled A Bahjri  1 , Mayada Aljehani  1 , Carlos A Garberoglio  2 , Mark E Reeves  2 , Jukes P Namm  2 , Naveenraj L Solomon  2 , Fabrizio Luca  2 , Crickett Dyke  3 , Maheswari Senthil  2
Affiliations

Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study

Brice Jabo et al. J Gastrointest Oncol. 2018 Feb.

Abstract

Background: Both perioperative chemotherapy (PC) and adjuvant chemoradiotherapy (CRT) improve survival in resectable gastric cancer; however, these treatments have never been formally compared. Our objective was to evaluate treatment trends and compare survival outcomes for gastric cancer patients treated with surgery and either PC or CRT.

Methods: We performed a retrospective population-based cohort study between 2007 through 2013 using California Cancer Registry data. Patients diagnosed with stage IB-III gastric adenocarcinoma and treated with total or partial gastrectomy were eligible for this study. Based on the type of treatment received, patients were grouped into surgery-only, PC, or CRT. Primary and secondary outcomes were overall survival (OS) and gastric cancer-specific survival (GCCS) respectively. Mortality hazards ratios (HRs) for each of these outcomes were computed using propensity score weighted and covariate-adjusted Cox regression models, stratified by clinical node status.

Results: Of 2,146 patients who underwent surgical resection, 1,067 had surgery-only, while 771 and 308 received PC or CRT, respectively. Median OS was 25, 33, and 52 months for surgery-only, PC, and CRT, respectively; P<0.001. Overall, patients treated with PC had significantly poorer survival compared to CRT (HR =1.45; 95% CI: 1.22-1.73). PC was also associated with higher mortality in patients with signet ring histology (HR =1.66; 95% CI: 1.21-2.28) and clinical node negative cancer (HR =1.85; 95% CI: 1.32-2.60). Survival was not different between PC vs. CRT in clinical node positive patients (HR =1.29; 95% CI: 0.84-2.08). Of note, the percentage of patients receiving PC increased from 17.5% in 2007-2008, to 41.5% in 2013-2014; P<0.001.

Conclusions: Despite the rapid adoption of PC, overall, CRT is associated with better survival than PC. Specifically, clinical node negative and signet ring histology patients had better survival when treated with CRT compared to PC. Based on these findings, we recommend against indiscriminate adoption of PC and consideration for CRT over PC in clinical node negative patients.

Keywords: Gastric cancer; adjuvant chemoradiotherapy (CRT); perioperative chemotherapy (PC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Patient selection flowchart.
Figure 2
Figure 2
Kaplan-Meier survival curves (A-C) and treatment trends (D) for adjuvant CRT, PC and surgery-only. CRT, chemoradiotherapy; PC, perioperative chemotherapy.
Figure 3
Figure 3
Mortality HRs comparing surgery-only, adjuvant CRT and PC. HRs, hazards ratios; CRT, chemoradiotherapy; PC, perioperative chemotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Global Burden of Disease Cancer Collaboration , Fitzmaurice C, Dicker D, et al. Global Burden of Disease Cancer C. The global burden of cancer 2013. JAMA Oncology 2015;1:505-27. 10.1001/jamaoncol.2015.0735 - DOI - PMC - PubMed
    1. Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer 2003;97:3133-275. 10.1002/cncr.11380 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. 10.3322/caac.21332 - DOI - PubMed
    1. Howlader N NA, Krapcho M, Garshell J, et al. editors. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute, 1975-2013.
    1. Ito H, Clancy TE, Osteen RT, et al. Adenocarcinoma of the gastric cardia: what is the optimal surgical approach? J Am Coll Surg 2004;199:880-6. 10.1016/j.jamcollsurg.2004.08.015 - DOI - PubMed